These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases]. Horký K Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582 [TBL] [Abstract][Full Text] [Related]
4. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
5. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. Horký K Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167 [TBL] [Abstract][Full Text] [Related]
6. Update on role of direct renin inhibitor in diabetic kidney disease. Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880 [TBL] [Abstract][Full Text] [Related]
7. [Renin inhibition and the kidney]. Ecder T Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474 [TBL] [Abstract][Full Text] [Related]
8. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333 [TBL] [Abstract][Full Text] [Related]
9. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy. Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034 [TBL] [Abstract][Full Text] [Related]
10. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity. Dalla Vestra M; Simioni N; Masiero A Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162 [TBL] [Abstract][Full Text] [Related]
11. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient? de la Sierra A; Salazar J Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181 [TBL] [Abstract][Full Text] [Related]
12. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis. Takenaka T; Okayama M; Kojima E; Nodaira Y; Arai J; Uchida K; Kikuta T; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H Clin Exp Hypertens; 2013; 35(4):244-9. PubMed ID: 23534458 [TBL] [Abstract][Full Text] [Related]
13. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. Doulton TW; MacGregor GA J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273 [TBL] [Abstract][Full Text] [Related]
14. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H; PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332 [TBL] [Abstract][Full Text] [Related]
15. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635 [TBL] [Abstract][Full Text] [Related]
16. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
17. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists. Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061 [TBL] [Abstract][Full Text] [Related]
18. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J; Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387 [TBL] [Abstract][Full Text] [Related]
19. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best? Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363 [TBL] [Abstract][Full Text] [Related]
20. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study. Szeto CC; Kwan BC; Chow KM; Leung CB; Li PK PLoS One; 2013; 8(5):e62736. PubMed ID: 23675422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]